BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) CEO Jean Jacques Bienaime sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $84.14, for a total value of $841,400.00. Following the completion of the sale, the chief executive officer now directly owns 335,324 shares of the company’s stock, valued at approximately $28,214,161.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Jean Jacques Bienaime also recently made the following trade(s):
- On Thursday, April 28th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $83.79, for a total value of $1,675,800.00.
- On Monday, April 18th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $81.91, for a total value of $1,638,200.00.
- On Thursday, April 14th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $83.66, for a total value of $836,600.00.
- On Thursday, March 10th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $77.57, for a total value of $1,163,550.00.
The U.S. and China are fighting for new sources of lithium – the linchpin of clean energy. Lithium mining operations have been declared a national emergency. Biden has ordered America’s lithium supply chain to be strengthened and investors in lithium exploration companies are rejoicing. We may be entering a decades-long lithium bull run. You don’t want to miss it.
Shares of NASDAQ BMRN traded down $4.64 during mid-day trading on Monday, reaching $74.62. 1,814,425 shares of the company’s stock were exchanged, compared to its average volume of 1,286,764. The firm has a market capitalization of $13.80 billion, a price-to-earnings ratio of 414.56, a PEG ratio of 1.66 and a beta of 0.41. The company has a current ratio of 4.88, a quick ratio of 2.77 and a debt-to-equity ratio of 0.25. The business has a fifty day simple moving average of $80.18 and a 200 day simple moving average of $83.70. BioMarin Pharmaceutical Inc. has a twelve month low of $71.59 and a twelve month high of $94.20.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.48. BioMarin Pharmaceutical had a return on equity of 1.36% and a net margin of 2.09%. During the same quarter in the prior year, the firm earned $0.29 earnings per share. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 0.94 earnings per share for the current fiscal year.
A number of brokerages recently commented on BMRN. Piper Sandler upped their target price on BioMarin Pharmaceutical from $121.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, February 24th. Truist Financial upped their price target on BioMarin Pharmaceutical from $125.00 to $135.00 in a research report on Monday, January 10th. Jefferies Financial Group reiterated a “buy” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Wednesday, May 4th. StockNews.com upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday. Finally, Morgan Stanley upgraded BioMarin Pharmaceutical from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $96.00 to $113.00 in a report on Monday, April 25th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Buy” and a consensus price target of $111.93.
Several large investors have recently bought and sold shares of BMRN. Norges Bank bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $207,582,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of BioMarin Pharmaceutical by 372.7% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,865,000 shares of the biotechnology company’s stock worth $164,773,000 after buying an additional 1,470,498 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $104,253,000. Camber Capital Management LP bought a new position in shares of BioMarin Pharmaceutical during the third quarter worth about $88,884,000. Finally, Jennison Associates LLC bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $48,817,000. Institutional investors and hedge funds own 95.45% of the company’s stock.
About BioMarin Pharmaceutical (Get Rating)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in BioMarin Pharmaceutical right now?
Before you consider BioMarin Pharmaceutical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and BioMarin Pharmaceutical wasn’t on the list.
While BioMarin Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $841,400.00 in Stock